Here’s a bold statement: The University of Maryland School of Medicine (UMSOM) just made a move that could reshape the future of biochemistry and molecular biology. But here’s where it gets exciting: Gerald M. Wilson, PhD, a globally recognized scientist and academic leader, has been named Chair of the Department of Biochemistry and Molecular Biology, effective December 15, 2025. This isn’t just another appointment—it’s a strategic leap forward for the school, as Dr. Wilson brings over two decades of groundbreaking research in RNA biochemistry and cancer mechanisms to the table. As part of this role, he’ll also hold the prestigious title of John F.B. Weaver Professor in Biochemistry and Molecular Biology.
Dr. Wilson’s journey at UMSOM began in 2002 as an Assistant Professor, and he’s since climbed the ranks, earning tenure in 2009 and becoming a full Professor in 2022. And this is the part most people miss: From 2011 to 2023, he led the combined University of Maryland (UMB/UMBC) Graduate Program in Biochemistry and Molecular Biology, shaping the next generation of biomedical researchers. His interim leadership of the department over the past two years has already demonstrated his ability to strengthen research initiatives and foster collaboration.
With over 80 peer-reviewed publications and an impressive h-index of 42, Dr. Wilson’s work has deepened our understanding of RNA-protein interactions, particularly their role in gene regulation and diseases like cancer and cardiovascular disorders. His research has been backed by major grants from the National Institutes of Health (NIH), the American Cancer Society, and the American Heart Association. Here’s where it gets controversial: His co-edited book, RNA-Based Mechanisms in Cancer (2023), and his U.S. patents for DNA ligase inhibitors aimed at cancer therapy, challenge traditional approaches to disease treatment—sparking debates about the future of targeted therapies. Are we on the brink of a revolution in cancer research, or is this just another step in a long journey?
Dean Mark T. Gladwin, MD, couldn’t be more enthusiastic about the appointment. “Gerald’s leadership as Interim Chair has been nothing short of transformative,” he said. “His vision for revitalizing drug discovery, expanding core facilities, and recruiting top-tier faculty aligns perfectly with our goals. I’m thrilled to see him continue this work as a key member of our leadership team.”
As Chair, Dr. Wilson aims to push boundaries in educational innovation, resource management, and inclusivity. He plans to foster a culture of mentorship and national engagement, ensuring the department’s discoveries translate into real-world healthcare improvements. But here’s the question: Can his ambitious plans bridge the gap between cutting-edge science and practical medical solutions? Only time will tell.
Dr. Wilson himself expressed gratitude for the opportunity, stating, “I’m honored to lead such a remarkable community of scholars. This is a chance to expand our expertise and strengthen collaborations across research, education, and service. I’m excited to see what we can achieve together.”
With a B.Sc. and Ph.D. in Biochemistry from Queen’s University in Canada, and postdoctoral training at Wake Forest University and the University of Medicine and Dentistry of New Jersey, Dr. Wilson’s credentials are as impressive as his vision. Here’s the final thought: As he steps into this new role, the question remains—will his leadership mark a new era in biochemistry and molecular biology? Share your thoughts in the comments—we’d love to hear your take on this pivotal appointment.
